Blog

Paul Sargos: TMT and concomitant Chemo regimen for patients with Muscle Invasive Bladder Cancer

Paul Sargos/X

Nov 25, 2024, 17:19

Paul Sargos: TMT and concomitant Chemo regimen for patients with Muscle Invasive Bladder Cancer

Paul Sargos, Head of the Radiology Department at Bergonie Institute, shared a post X about recent paper by him as co-author, titled “Concomitant Chemotherapy in Trimodal Treatment of Patients with Muscle Invasive Bladder Cancer: A Systematic Review of Prospective Trials” published on Science Direct.

Authors: Camille Baudelin, Paul Sargos, Derek Dinart, Christophe Hennequin, Diego Teyssonneau, Lucie Meynard, Nam-Son Vuong, Félix Lefort, Michael Baboudjian, Guilhem Roubaud.

“Our systematic review focusing on TMT and concomitant Chemo regimen for patients with MIBC

Heterogeneity ++
Overall, similar OS and safety outcomes
Highest LOE=5FU-Mitomycin C
Data regarding elderly patients and QOL insufficiently reported.”

Camille Baudelin cancer Christophe Hennequin Derek Dinart Diego Teyssonneau Félix Lefort Guilhem Roubaud Lucie Meynard Michael Baboudjian muscle invasive bladder cancer Nam-Son Vuong OncoDaily Oncology Paul Sargos Science Direct

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care